Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 545

Results For "GE"

8414 News Found

Suburban Diagnostics unveils Reference Laboratory in Mumbai
Clinical Trials | January 09, 2023

Suburban Diagnostics unveils Reference Laboratory in Mumbai

The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab


AIIMS Bhubaneswar provides quality healthcare service in Eastern India: Dr Mandaviya
News | January 09, 2023

AIIMS Bhubaneswar provides quality healthcare service in Eastern India: Dr Mandaviya

Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students


KIMS invests further in Sarvejana Healthcare
News | January 07, 2023

KIMS invests further in Sarvejana Healthcare

The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Dabur India expects low to mid-single digit revenue growth for Q3 FY23
News | January 07, 2023

Dabur India expects low to mid-single digit revenue growth for Q3 FY23

International Business is expected to post double-digit revenue growth during the quarter in constant currency.


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


ANSSI Wellness inaugurates new spine health facility in Nashik
Healthcare | January 07, 2023

ANSSI Wellness inaugurates new spine health facility in Nashik

ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Provention Bio appoints Rita Jain to Board of Directors
People | January 06, 2023

Provention Bio appoints Rita Jain to Board of Directors

Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co